IP Library Granted Patent US 11,326,210
Granted Patent B2
US 11,326,210 · App. 15/547,069 · Granted May 10, 2022

Compositions and methods for monitoring, diagnosis, prognosis, detection, and treatment of cancer

Inventors: Shivani Shrivastava (Wilmington, DE); Rakesh K Srivastava (Tyler, TX)
Assignee: GLAX LLC
C12Q1/6886A61K31/7052A61K31/713A61K45/06C12Q1/6883G01N33/57407G01N33/57496C12N15/113C12N2310/11C12N2310/14C12N2310/141C12N2320/30C12Q2600/106C12Q2600/112C12Q2600/158G01N2333/4703G01N2800/7095
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,326,210
App. No.
15/547,069
Granted
May 10, 2022
Kind
B2
Abstract

The present invention relates to the field of cancer and inflammation, and in particular methods of monitoring, diagnosis, prognosis, detecting, treating and preventing cancer and inflammation conditions. The use of composition comprises method of monitoring, diagnosis, prognosis, and detecting cancer and inflammation with EN2 and/or SATB2 expression and/or activity. The pharmaceutical composition will further comprise agents that inhibit EN2 and/or SATB2 expression or activity.

Claims (8)

1. A method for treating or preventing cancer in a subject, comprising administering to the subject a pharmaceutical composition comprising an effective amount of at least one agent that inhibits at least one of EN2 expression, EN2 transcriptional activity, SATB2 expression, or SATB2 transcriptional activity, wherein

SATB2 and EN2 are highly expressed in the cancer, and

the at least one agent is a small organic molecule represented by a compound having the chemical structure of

2. The method of claim 1 , wherein the at least one agent comprises a targeting moiety capable of binding to a surface of a cancer cell, wherein the targeting moiety is selected from the group consisting of aptamers, peptides, biodegradable materials, antibody-derived epitope binding domains, cellular ligands, and combination thereof.

3. The method of claim 1 , wherein the method further comprises:

determining EN2 and/or SATB2 expression level of said subject.

4. The method of claim 1 , wherein the at least one agent is administered in nanoparticles.

5. The method of claim 1 , wherein the at least one agent is administered to the subject in combination with one or more chemotherapeutic drugs or radiation for treatment and prevention of cancer.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 9, 2026
From: SRIVASTAVA, RAKESH K.; SHRIVASTAVA, SHIVANI
To: GLAX HEALTH LLC
Reel/Frame 075954/0735 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 23, 2018
From: SHRIVASTAVA, SHIVANI
To: GLAX LLC
Reel/Frame 045322/0315 →
Continuity (2)
Provisional Application 62110153 · Jan 30, 2015
Related Publication 20180010195A1 · Jan 11, 2018